Lenalidomide Bypasses CD28 Co-Stimulation to Reinstate PD-1 Immunotherapy by Activating Notch Signaling

Using a cereblon knockin mouse model that regained in vivo T cell response to lenalidomide, an immunomodulatory imide drug, the authors showed that lenalidomide reinstated the anti-tumor activity of CD28-deficient CD8+ T cells after rogrammed cell death protein 1 (PD-1) blockade.